Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−11.34 SEK
−831.72 M SEK
134.09 M SEK
57.73 M
About HANSA BIOPHARMA AB
Sector
CEO
Søren Tulstrup
Headquarters
Lund
Website
Founded
2007
ISIN
SE0002148817
FIGI
BBG000QCYH36
Hansa Biopharma AB focuses on novel immunomodulatory enzymes, which treat rare immunoglobulin G-mediated autoimmune conditions, transplant rejection and cancer. Its pipeline includes IdeS, HBP-assay, EnzE, and NiceR. The company was founded by Lars Björck and Bo Krister Håkansson in 2001 and is headquartered in Lund, Sweden.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of HNSA is 29.88 SEK — it has increased by 1.24% in the past 24 hours. Watch HANSA BIOPHARMA AB stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OMXSTO exchange HANSA BIOPHARMA AB stocks are traded under the ticker HNSA.
HNSA stock has fallen by −6.40% compared to the previous week, the month change is a −23.58% fall, over the last year HANSA BIOPHARMA AB has showed a 8.58% increase.
We've gathered analysts' opinions on HANSA BIOPHARMA AB future price: according to them, HNSA price has a max estimate of 175.00 SEK and a min estimate of 56.00 SEK. Watch HNSA chart and read a more detailed HANSA BIOPHARMA AB stock forecast: see what analysts think of HANSA BIOPHARMA AB and suggest that you do with its stocks.
HNSA reached its all-time high on Oct 4, 2018 with the price of 349.40 SEK, and its all-time low was 2.26 SEK and was reached on Oct 23, 2012. View more price dynamics on HNSA chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
HNSA stock is 4.10% volatile and has beta coefficient of 1.00. Track HANSA BIOPHARMA AB stock price on the chart and check out the list of the most volatile stocks — is HANSA BIOPHARMA AB there?
Today HANSA BIOPHARMA AB has the market capitalization of 2.08 B, it has decreased by −7.33% over the last week.
Yes, you can track HANSA BIOPHARMA AB financials in yearly and quarterly reports right on TradingView.
HANSA BIOPHARMA AB is going to release the next earnings report on Feb 6, 2025. Keep track of upcoming events with our Earnings Calendar.
HNSA earnings for the last quarter are −1.53 SEK per share, whereas the estimation was −2.42 SEK resulting in a 36.69% surprise. The estimated earnings for the next quarter are −1.84 SEK per share. See more details about HANSA BIOPHARMA AB earnings.
HANSA BIOPHARMA AB revenue for the last quarter amounts to 48.70 M SEK, despite the estimated figure of 54.21 M SEK. In the next quarter, revenue is expected to reach 81.48 M SEK.
HNSA net income for the last quarter is −103.80 M SEK, while the quarter before that showed −207.94 M SEK of net income which accounts for 50.08% change. Track more HANSA BIOPHARMA AB financial stats to get the full picture.
No, HNSA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 22, 2024, the company has 168.00 employees. See our rating of the largest employees — is HANSA BIOPHARMA AB on this list?
Like other stocks, HNSA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade HANSA BIOPHARMA AB stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So HANSA BIOPHARMA AB technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating HANSA BIOPHARMA AB stock shows the strong sell signal. See more of HANSA BIOPHARMA AB technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.